slc38a1 Search Results


gene exp slc38a1 mm00506391 m1  (Thermo Fisher)
86
Thermo Fisher gene exp slc38a1 mm00506391 m1
Gene Exp Slc38a1 Mm00506391 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/slc38a1/Gene+Exp%2E+slc38a1+mm00506391+m1/pmc06943234-51-17--1
Average 86 stars, based on 1 article reviews
gene exp slc38a1 mm00506391 m1 - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
slc38a1  (Bioss)
91
Bioss slc38a1
Slc38a1, supplied by Bioss, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/slc38a1/SLC38A1+Polyclonal+Antibody/pmc11311365-332-80-81
Average 91 stars, based on 1 article reviews
slc38a1 - by Bioz Stars, 2026-09
91/100 stars
  Buy from Supplier
snat1  (Novus Biologicals)
91
Novus Biologicals snat1
Fig. 4 Levels of the placental mature form of the SNAT2 protein are reduced in SGA newborns. Placental mRNA levels of <t>SNAT1</t> (SLC38A1) (A), SNAT2 (SLC38A2) (B), and LAT1 (SLC7A5) (C). Placental membrane cell lysate extracts were assayed via western blot analysis with antibodies against SNAT1 (D), SNAT2 (E), and LAT1 (F). Data (N = 10) are presented as the mean ± SEM. * p < 0.05 and *** p < 0.001 versus the AGA group. P-values determined by two-tailed unpaired Student’s t-test
Snat1, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/slc38a1/SLC38A1+Antibody+(S104-32)/pm37957724-87-121-122
Average 91 stars, based on 1 article reviews
snat1 - by Bioz Stars, 2026-09
91/100 stars
  Buy from Supplier
slc38a1  (Cell Signaling Technology Inc)
94
Cell Signaling Technology Inc slc38a1
Fig. 6 ALK signaling upregulates amino acid transporter systems. Gene oncology GSEA analysis of RNA-seq datasets. A NB tumors from either Alk-F1178S;Th-MYCN mice or Rosa26_Alkal2;Th-MYCN mice compared to Th-MYCN mice. B NB1 cells treated with either ALKAL2 or/and lorlatinib for 24 h. C CLB-BAR cells treated with lorlatinib for 24 h compared to DMSO treated control. D Heat map indicating biotinylation of SLC1A5, SLC3A2, SLC6A15, <t>SLC38A1</t> in SK-N-AS.ALK-BirA* expressing cells compared to BirA* controls. Columns represent three biological replicates, data from [41]. Immunoblotting for anti-pALK (Y1278), SLC1A5, SLC3A2, SLC7A5, SLC7A11, SLC38A1 and GAPDH in NB1 cells treated with ALKAL2 (1 µg/ml) and lorlatinib (0 or 30 nM) for 24 h (E) and CLB-BAR cells treated with lorlatinib (0, 30 nM) for 24 h (F). G Schematic visualization of the regulation of SLC3A2 downstream of ALK in NB cells (created with BioRender.com). Immunoblot experiments were performed in biologically independent triplicates. Quantifications were performed with ImageJ and analyzed by Student t test (unpaired, two- tailed). p values are indicated (****P < 0.0001, ***0.0001 < P < 0.001, **0.001 < P < 0.01, *0.01 < P < 0.05, ns P ≥0.05); exact P values are shown in Supplementary Fig. 5 and Supplementary Table 1.
Slc38a1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/slc38a1/SNAT1%2FSLC38A1+Rabbit+mAb/pm38858548-203-64-81
Average 94 stars, based on 1 article reviews
slc38a1 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
anti snat 1  (Proteintech)
94
Proteintech anti snat 1
Fig. 6 ALK signaling upregulates amino acid transporter systems. Gene oncology GSEA analysis of RNA-seq datasets. A NB tumors from either Alk-F1178S;Th-MYCN mice or Rosa26_Alkal2;Th-MYCN mice compared to Th-MYCN mice. B NB1 cells treated with either ALKAL2 or/and lorlatinib for 24 h. C CLB-BAR cells treated with lorlatinib for 24 h compared to DMSO treated control. D Heat map indicating biotinylation of SLC1A5, SLC3A2, SLC6A15, <t>SLC38A1</t> in SK-N-AS.ALK-BirA* expressing cells compared to BirA* controls. Columns represent three biological replicates, data from [41]. Immunoblotting for anti-pALK (Y1278), SLC1A5, SLC3A2, SLC7A5, SLC7A11, SLC38A1 and GAPDH in NB1 cells treated with ALKAL2 (1 µg/ml) and lorlatinib (0 or 30 nM) for 24 h (E) and CLB-BAR cells treated with lorlatinib (0, 30 nM) for 24 h (F). G Schematic visualization of the regulation of SLC3A2 downstream of ALK in NB cells (created with BioRender.com). Immunoblot experiments were performed in biologically independent triplicates. Quantifications were performed with ImageJ and analyzed by Student t test (unpaired, two- tailed). p values are indicated (****P < 0.0001, ***0.0001 < P < 0.001, **0.001 < P < 0.01, *0.01 < P < 0.05, ns P ≥0.05); exact P values are shown in Supplementary Fig. 5 and Supplementary Table 1.
Anti Snat 1, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/slc38a1/SLC38A1+Antibody/pm36870594-93-40-42
Average 94 stars, based on 1 article reviews
anti snat 1 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
slc38a1 cdna clones  (OriGene)
90
OriGene slc38a1 cdna clones
Fig. 6 ALK signaling upregulates amino acid transporter systems. Gene oncology GSEA analysis of RNA-seq datasets. A NB tumors from either Alk-F1178S;Th-MYCN mice or Rosa26_Alkal2;Th-MYCN mice compared to Th-MYCN mice. B NB1 cells treated with either ALKAL2 or/and lorlatinib for 24 h. C CLB-BAR cells treated with lorlatinib for 24 h compared to DMSO treated control. D Heat map indicating biotinylation of SLC1A5, SLC3A2, SLC6A15, <t>SLC38A1</t> in SK-N-AS.ALK-BirA* expressing cells compared to BirA* controls. Columns represent three biological replicates, data from [41]. Immunoblotting for anti-pALK (Y1278), SLC1A5, SLC3A2, SLC7A5, SLC7A11, SLC38A1 and GAPDH in NB1 cells treated with ALKAL2 (1 µg/ml) and lorlatinib (0 or 30 nM) for 24 h (E) and CLB-BAR cells treated with lorlatinib (0, 30 nM) for 24 h (F). G Schematic visualization of the regulation of SLC3A2 downstream of ALK in NB cells (created with BioRender.com). Immunoblot experiments were performed in biologically independent triplicates. Quantifications were performed with ImageJ and analyzed by Student t test (unpaired, two- tailed). p values are indicated (****P < 0.0001, ***0.0001 < P < 0.001, **0.001 < P < 0.01, *0.01 < P < 0.05, ns P ≥0.05); exact P values are shown in Supplementary Fig. 5 and Supplementary Table 1.
Slc38a1 Cdna Clones, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/slc38a1/SLC38A1+(NM_001077484)+Human+Tagged+ORF+Clone/pmc04881866-88-3-9
Average 90 stars, based on 1 article reviews
slc38a1 cdna clones - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
anti slc38a1 snat1  (Novus Biologicals)
93
Novus Biologicals anti slc38a1 snat1
Fig. 6 ALK signaling upregulates amino acid transporter systems. Gene oncology GSEA analysis of RNA-seq datasets. A NB tumors from either Alk-F1178S;Th-MYCN mice or Rosa26_Alkal2;Th-MYCN mice compared to Th-MYCN mice. B NB1 cells treated with either ALKAL2 or/and lorlatinib for 24 h. C CLB-BAR cells treated with lorlatinib for 24 h compared to DMSO treated control. D Heat map indicating biotinylation of SLC1A5, SLC3A2, SLC6A15, <t>SLC38A1</t> in SK-N-AS.ALK-BirA* expressing cells compared to BirA* controls. Columns represent three biological replicates, data from [41]. Immunoblotting for anti-pALK (Y1278), SLC1A5, SLC3A2, SLC7A5, SLC7A11, SLC38A1 and GAPDH in NB1 cells treated with ALKAL2 (1 µg/ml) and lorlatinib (0 or 30 nM) for 24 h (E) and CLB-BAR cells treated with lorlatinib (0, 30 nM) for 24 h (F). G Schematic visualization of the regulation of SLC3A2 downstream of ALK in NB cells (created with BioRender.com). Immunoblot experiments were performed in biologically independent triplicates. Quantifications were performed with ImageJ and analyzed by Student t test (unpaired, two- tailed). p values are indicated (****P < 0.0001, ***0.0001 < P < 0.001, **0.001 < P < 0.01, *0.01 < P < 0.05, ns P ≥0.05); exact P values are shown in Supplementary Fig. 5 and Supplementary Table 1.
Anti Slc38a1 Snat1, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/slc38a1/SLC38A1+Antibody/pm37614038-218-162-163
Average 93 stars, based on 1 article reviews
anti slc38a1 snat1 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
gene exp slc38a1 hs01562175 m1  (Thermo Fisher)
91
Thermo Fisher gene exp slc38a1 hs01562175 m1
Fig. 6 ALK signaling upregulates amino acid transporter systems. Gene oncology GSEA analysis of RNA-seq datasets. A NB tumors from either Alk-F1178S;Th-MYCN mice or Rosa26_Alkal2;Th-MYCN mice compared to Th-MYCN mice. B NB1 cells treated with either ALKAL2 or/and lorlatinib for 24 h. C CLB-BAR cells treated with lorlatinib for 24 h compared to DMSO treated control. D Heat map indicating biotinylation of SLC1A5, SLC3A2, SLC6A15, <t>SLC38A1</t> in SK-N-AS.ALK-BirA* expressing cells compared to BirA* controls. Columns represent three biological replicates, data from [41]. Immunoblotting for anti-pALK (Y1278), SLC1A5, SLC3A2, SLC7A5, SLC7A11, SLC38A1 and GAPDH in NB1 cells treated with ALKAL2 (1 µg/ml) and lorlatinib (0 or 30 nM) for 24 h (E) and CLB-BAR cells treated with lorlatinib (0, 30 nM) for 24 h (F). G Schematic visualization of the regulation of SLC3A2 downstream of ALK in NB cells (created with BioRender.com). Immunoblot experiments were performed in biologically independent triplicates. Quantifications were performed with ImageJ and analyzed by Student t test (unpaired, two- tailed). p values are indicated (****P < 0.0001, ***0.0001 < P < 0.001, **0.001 < P < 0.01, *0.01 < P < 0.05, ns P ≥0.05); exact P values are shown in Supplementary Fig. 5 and Supplementary Table 1.
Gene Exp Slc38a1 Hs01562175 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/slc38a1/Gene+Exp%2E+slc38a1+hs01562175+m1/10__1074_slash_jbc__ra117__000735-213-27--1
Average 91 stars, based on 1 article reviews
gene exp slc38a1 hs01562175 m1 - by Bioz Stars, 2026-09
91/100 stars
  Buy from Supplier
gene exp slc38a1 hs01562168 m1  (Thermo Fisher)
86
Thermo Fisher gene exp slc38a1 hs01562168 m1
Fig. 6 ALK signaling upregulates amino acid transporter systems. Gene oncology GSEA analysis of RNA-seq datasets. A NB tumors from either Alk-F1178S;Th-MYCN mice or Rosa26_Alkal2;Th-MYCN mice compared to Th-MYCN mice. B NB1 cells treated with either ALKAL2 or/and lorlatinib for 24 h. C CLB-BAR cells treated with lorlatinib for 24 h compared to DMSO treated control. D Heat map indicating biotinylation of SLC1A5, SLC3A2, SLC6A15, <t>SLC38A1</t> in SK-N-AS.ALK-BirA* expressing cells compared to BirA* controls. Columns represent three biological replicates, data from [41]. Immunoblotting for anti-pALK (Y1278), SLC1A5, SLC3A2, SLC7A5, SLC7A11, SLC38A1 and GAPDH in NB1 cells treated with ALKAL2 (1 µg/ml) and lorlatinib (0 or 30 nM) for 24 h (E) and CLB-BAR cells treated with lorlatinib (0, 30 nM) for 24 h (F). G Schematic visualization of the regulation of SLC3A2 downstream of ALK in NB cells (created with BioRender.com). Immunoblot experiments were performed in biologically independent triplicates. Quantifications were performed with ImageJ and analyzed by Student t test (unpaired, two- tailed). p values are indicated (****P < 0.0001, ***0.0001 < P < 0.001, **0.001 < P < 0.01, *0.01 < P < 0.05, ns P ≥0.05); exact P values are shown in Supplementary Fig. 5 and Supplementary Table 1.
Gene Exp Slc38a1 Hs01562168 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/slc38a1/Gene+Exp%2E+SLC38A1%2C+Hs01562168_m1/pm30334568-49-17-31
Average 86 stars, based on 1 article reviews
gene exp slc38a1 hs01562168 m1 - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
anti-slc38a1  (GeneTex)
90
GeneTex anti-slc38a1
Fig. 6 ALK signaling upregulates amino acid transporter systems. Gene oncology GSEA analysis of RNA-seq datasets. A NB tumors from either Alk-F1178S;Th-MYCN mice or Rosa26_Alkal2;Th-MYCN mice compared to Th-MYCN mice. B NB1 cells treated with either ALKAL2 or/and lorlatinib for 24 h. C CLB-BAR cells treated with lorlatinib for 24 h compared to DMSO treated control. D Heat map indicating biotinylation of SLC1A5, SLC3A2, SLC6A15, <t>SLC38A1</t> in SK-N-AS.ALK-BirA* expressing cells compared to BirA* controls. Columns represent three biological replicates, data from [41]. Immunoblotting for anti-pALK (Y1278), SLC1A5, SLC3A2, SLC7A5, SLC7A11, SLC38A1 and GAPDH in NB1 cells treated with ALKAL2 (1 µg/ml) and lorlatinib (0 or 30 nM) for 24 h (E) and CLB-BAR cells treated with lorlatinib (0, 30 nM) for 24 h (F). G Schematic visualization of the regulation of SLC3A2 downstream of ALK in NB cells (created with BioRender.com). Immunoblot experiments were performed in biologically independent triplicates. Quantifications were performed with ImageJ and analyzed by Student t test (unpaired, two- tailed). p values are indicated (****P < 0.0001, ***0.0001 < P < 0.001, **0.001 < P < 0.01, *0.01 < P < 0.05, ns P ≥0.05); exact P values are shown in Supplementary Fig. 5 and Supplementary Table 1.
Anti Slc38a1, supplied by GeneTex, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/slc38a1/anti+slc38a1/ppr0956627-29-11-15
Average 90 stars, based on 1 article reviews
anti-slc38a1 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
anti-slc38a1 sirnas  (Shanghai GenePharma)
90
Shanghai GenePharma anti-slc38a1 sirnas
Fig. 6 ALK signaling upregulates amino acid transporter systems. Gene oncology GSEA analysis of RNA-seq datasets. A NB tumors from either Alk-F1178S;Th-MYCN mice or Rosa26_Alkal2;Th-MYCN mice compared to Th-MYCN mice. B NB1 cells treated with either ALKAL2 or/and lorlatinib for 24 h. C CLB-BAR cells treated with lorlatinib for 24 h compared to DMSO treated control. D Heat map indicating biotinylation of SLC1A5, SLC3A2, SLC6A15, <t>SLC38A1</t> in SK-N-AS.ALK-BirA* expressing cells compared to BirA* controls. Columns represent three biological replicates, data from [41]. Immunoblotting for anti-pALK (Y1278), SLC1A5, SLC3A2, SLC7A5, SLC7A11, SLC38A1 and GAPDH in NB1 cells treated with ALKAL2 (1 µg/ml) and lorlatinib (0 or 30 nM) for 24 h (E) and CLB-BAR cells treated with lorlatinib (0, 30 nM) for 24 h (F). G Schematic visualization of the regulation of SLC3A2 downstream of ALK in NB cells (created with BioRender.com). Immunoblot experiments were performed in biologically independent triplicates. Quantifications were performed with ImageJ and analyzed by Student t test (unpaired, two- tailed). p values are indicated (****P < 0.0001, ***0.0001 < P < 0.001, **0.001 < P < 0.01, *0.01 < P < 0.05, ns P ≥0.05); exact P values are shown in Supplementary Fig. 5 and Supplementary Table 1.
Anti Slc38a1 Sirnas, supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/slc38a1/anti+slc38a1+sirnas/10__1186_slash_1471___230x___14___70-63-3-16
Average 90 stars, based on 1 article reviews
anti-slc38a1 sirnas - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Fig. 4 Levels of the placental mature form of the SNAT2 protein are reduced in SGA newborns. Placental mRNA levels of SNAT1 (SLC38A1) (A), SNAT2 (SLC38A2) (B), and LAT1 (SLC7A5) (C). Placental membrane cell lysate extracts were assayed via western blot analysis with antibodies against SNAT1 (D), SNAT2 (E), and LAT1 (F). Data (N = 10) are presented as the mean ± SEM. * p < 0.05 and *** p < 0.001 versus the AGA group. P-values determined by two-tailed unpaired Student’s t-test

Journal: Cell communication and signaling : CCS

Article Title: CHOP upregulation and dysregulation of the mature form of the SNAT2 amino acid transporter in the placentas from small for gestational age newborns.

doi: 10.1186/s12964-023-01352-5

Figure Lengend Snippet: Fig. 4 Levels of the placental mature form of the SNAT2 protein are reduced in SGA newborns. Placental mRNA levels of SNAT1 (SLC38A1) (A), SNAT2 (SLC38A2) (B), and LAT1 (SLC7A5) (C). Placental membrane cell lysate extracts were assayed via western blot analysis with antibodies against SNAT1 (D), SNAT2 (E), and LAT1 (F). Data (N = 10) are presented as the mean ± SEM. * p < 0.05 and *** p < 0.001 versus the AGA group. P-values determined by two-tailed unpaired Student’s t-test

Article Snippet: Immunoblotting was performed with antibodies against β-actin (Sigma, A5441), 4EBP1 (Cell Signalling, 9452), AKT (Cell Signalling, 9272), AMPKα (Cell Signalling, 2532), ATF4 (Santa Cruz Biotechnology, sc-200), ATF6 (Santa Cruz Biotechnology, sc-22799), BiP/GRP78 (Cell Signalling, 3183), CHOP (Cell Signalling, 2895), eIF2α (Cell Signalling, 9722), ERK1/2 (44/42 MAPK) (Cell Signalling, 9102), GADD34 (Cell Signalling, sc-46661), GAPDH (Millipore, MAB374), GRASP55 (Proteintech, 66,627–1-Ig), LAT1 (Cell Signalling, 5347), mTOR (Cell Signalling, 2972), Na–K-ATPase (Santa Cruz Biotechnology, sc-514614), NEDD4-L (Cell Signalling, sc-514954), phospho-4EBP1 Thr37/46 (Cell Signalling, 2855), phospho-AKT Ser473 (Cell Signalling, 9271), phospho-AMPKα Thr172 (Cell Signalling, 2531), phospho-ERK1/2 (44/42 MAPK) Thr202/Tyr204 (Cell Signalling, 9101), phospho-IRE Ser724 (Novus Biologicals, NB100-2323), phospho-mTOR Ser2448 (Santa Cruz Biotechnology, sc-101738), phospho-ribosomal protein S6 (Cell Signalling, 2211), ribosomal protein S6 (Cell Signalling, 2317), SNAT1 (Novus Biologicals, NBP-2–59311), SNAT2 (MBL, BMP081), and vinculin (Santa Cruz Biotechnology, sc-73614).

Techniques: Membrane, Western Blot, Two Tailed Test

Fig. 5 GADD34 inhibition by guanabenz attenuates the reduction in mTORC1 activity and the increase in CHOP levels caused by ER stress in the human placental cell line BeWo. BeWo cells were stimulated with 0.1 μg/ml of tunicamycin (TM) either in the presence or absence of 5 μM guanabenz (GB) for 24 h and the protein levels of total and phosphorylated RPS6 (A), CHOP (B), SNAT1 (C), and SNAT2 (D) were assessed. Data (N = 3) are presented as the mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001 versus the AGA group. P-values determined by two-tailed unpaired Student’s t-test

Journal: Cell communication and signaling : CCS

Article Title: CHOP upregulation and dysregulation of the mature form of the SNAT2 amino acid transporter in the placentas from small for gestational age newborns.

doi: 10.1186/s12964-023-01352-5

Figure Lengend Snippet: Fig. 5 GADD34 inhibition by guanabenz attenuates the reduction in mTORC1 activity and the increase in CHOP levels caused by ER stress in the human placental cell line BeWo. BeWo cells were stimulated with 0.1 μg/ml of tunicamycin (TM) either in the presence or absence of 5 μM guanabenz (GB) for 24 h and the protein levels of total and phosphorylated RPS6 (A), CHOP (B), SNAT1 (C), and SNAT2 (D) were assessed. Data (N = 3) are presented as the mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001 versus the AGA group. P-values determined by two-tailed unpaired Student’s t-test

Article Snippet: Immunoblotting was performed with antibodies against β-actin (Sigma, A5441), 4EBP1 (Cell Signalling, 9452), AKT (Cell Signalling, 9272), AMPKα (Cell Signalling, 2532), ATF4 (Santa Cruz Biotechnology, sc-200), ATF6 (Santa Cruz Biotechnology, sc-22799), BiP/GRP78 (Cell Signalling, 3183), CHOP (Cell Signalling, 2895), eIF2α (Cell Signalling, 9722), ERK1/2 (44/42 MAPK) (Cell Signalling, 9102), GADD34 (Cell Signalling, sc-46661), GAPDH (Millipore, MAB374), GRASP55 (Proteintech, 66,627–1-Ig), LAT1 (Cell Signalling, 5347), mTOR (Cell Signalling, 2972), Na–K-ATPase (Santa Cruz Biotechnology, sc-514614), NEDD4-L (Cell Signalling, sc-514954), phospho-4EBP1 Thr37/46 (Cell Signalling, 2855), phospho-AKT Ser473 (Cell Signalling, 9271), phospho-AMPKα Thr172 (Cell Signalling, 2531), phospho-ERK1/2 (44/42 MAPK) Thr202/Tyr204 (Cell Signalling, 9101), phospho-IRE Ser724 (Novus Biologicals, NB100-2323), phospho-mTOR Ser2448 (Santa Cruz Biotechnology, sc-101738), phospho-ribosomal protein S6 (Cell Signalling, 2211), ribosomal protein S6 (Cell Signalling, 2317), SNAT1 (Novus Biologicals, NBP-2–59311), SNAT2 (MBL, BMP081), and vinculin (Santa Cruz Biotechnology, sc-73614).

Techniques: Inhibition, Activity Assay, Two Tailed Test

Fig. 6 ALK signaling upregulates amino acid transporter systems. Gene oncology GSEA analysis of RNA-seq datasets. A NB tumors from either Alk-F1178S;Th-MYCN mice or Rosa26_Alkal2;Th-MYCN mice compared to Th-MYCN mice. B NB1 cells treated with either ALKAL2 or/and lorlatinib for 24 h. C CLB-BAR cells treated with lorlatinib for 24 h compared to DMSO treated control. D Heat map indicating biotinylation of SLC1A5, SLC3A2, SLC6A15, SLC38A1 in SK-N-AS.ALK-BirA* expressing cells compared to BirA* controls. Columns represent three biological replicates, data from [41]. Immunoblotting for anti-pALK (Y1278), SLC1A5, SLC3A2, SLC7A5, SLC7A11, SLC38A1 and GAPDH in NB1 cells treated with ALKAL2 (1 µg/ml) and lorlatinib (0 or 30 nM) for 24 h (E) and CLB-BAR cells treated with lorlatinib (0, 30 nM) for 24 h (F). G Schematic visualization of the regulation of SLC3A2 downstream of ALK in NB cells (created with BioRender.com). Immunoblot experiments were performed in biologically independent triplicates. Quantifications were performed with ImageJ and analyzed by Student t test (unpaired, two- tailed). p values are indicated (****P < 0.0001, ***0.0001 < P < 0.001, **0.001 < P < 0.01, *0.01 < P < 0.05, ns P ≥0.05); exact P values are shown in Supplementary Fig. 5 and Supplementary Table 1.

Journal: Cell death and differentiation

Article Title: Anaplastic Lymphoma Kinase signaling stabilizes SLC3A2 expression via MARCH11 to promote neuroblastoma cell growth.

doi: 10.1038/s41418-024-01319-0

Figure Lengend Snippet: Fig. 6 ALK signaling upregulates amino acid transporter systems. Gene oncology GSEA analysis of RNA-seq datasets. A NB tumors from either Alk-F1178S;Th-MYCN mice or Rosa26_Alkal2;Th-MYCN mice compared to Th-MYCN mice. B NB1 cells treated with either ALKAL2 or/and lorlatinib for 24 h. C CLB-BAR cells treated with lorlatinib for 24 h compared to DMSO treated control. D Heat map indicating biotinylation of SLC1A5, SLC3A2, SLC6A15, SLC38A1 in SK-N-AS.ALK-BirA* expressing cells compared to BirA* controls. Columns represent three biological replicates, data from [41]. Immunoblotting for anti-pALK (Y1278), SLC1A5, SLC3A2, SLC7A5, SLC7A11, SLC38A1 and GAPDH in NB1 cells treated with ALKAL2 (1 µg/ml) and lorlatinib (0 or 30 nM) for 24 h (E) and CLB-BAR cells treated with lorlatinib (0, 30 nM) for 24 h (F). G Schematic visualization of the regulation of SLC3A2 downstream of ALK in NB cells (created with BioRender.com). Immunoblot experiments were performed in biologically independent triplicates. Quantifications were performed with ImageJ and analyzed by Student t test (unpaired, two- tailed). p values are indicated (****P < 0.0001, ***0.0001 < P < 0.001, **0.001 < P < 0.01, *0.01 < P < 0.05, ns P ≥0.05); exact P values are shown in Supplementary Fig. 5 and Supplementary Table 1.

Article Snippet: Primary antibodies against human SLC3A2 (#81977, was employed for immunoblotting, 1:2000; #13180, was used for immunoprecipitation), ALK (#3633, 1:2000), pALK (Y1278, #6941, 1:1000), ubiquitin (#3936, 1:1000), phospho-Tyrosine (p-Y-1000, #8954, 1:1000), pAKT (S473,#4060, 1:4000), AKT (#9272), pERK1/2 (Y204/T202, #4377, 1;2000), PARP (#9542, 1:1000), γH2A.X (Ser139, #9718, 1:1000), RET (#14556, 1:2000), DLG2 (#19046, 1:1000), SLC1A5 (ASCT2, #8057, 1:2000), SLC7A5 (LAT1, #32683, 1:1000), SLC7A11 (xCT, #12691, 1:1000), SLC38A1 (SNAT1, #36057, 1:2000), β-actin (#4970, 1:10000), GAPDH (#5174, 1:10,000) and α-tubulin (#2125, 1:10,000) were obtained from Cell Signaling Technology.

Techniques: RNA Sequencing, Control, Expressing, Western Blot, Two Tailed Test